ArticleJournal of hematopathology2026
Large B-cell lymphoma with IRF4 rearrangement: clinicopathologic heterogeneity across the age spectrum.
Article in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLarge B-cell lymphoma with IRF4 rearrangement (IRF4-R LBCL) is a rare entity recognised in the current WHO-HAEM5 classification and the International Consensus Classification (ICC). PURPOSE: This study aimed to evaluate the clinicopathologic and fluorescence in situ hybridisation (FISH) findings of IRF4-R LBCL across a broad age spectrum. MATERIALS AND
methodsSeven cases diagnosed with IRF4-R LBCL at the Department of Pathology, Hacettepe University Faculty of Medicine, were retrospectively reviewed. Clinical, morphological, immunohistochemical, and FISH findings were evaluated.
resultsPatients' ages ranged from 13 to 77 years; three were aged 40 years or older. Cases under 40 years of age were localised to the head and neck region and gastrointestinal tract, and all remained in remission. In contrast, cases aged 40 years or older demonstrated more heterogeneous anatomical distribution and clinical behaviour, with one disease-related death during follow-up. Immunohistochemical analysis showed CD20 and MUM1/IRF4 positivity in all cases, whilst CD10, BCL6, and BCL2 expression was variable. IRF4 rearrangement was identified in all cases. MYC and BCL2 rearrangements were absent in all cases, whereas BCL6 rearrangement was detected in one adult patient and could not be assessed in one case.
conclusionConsistent with the literature, IRF4-R LBCL in children and young adults generally shows a favourable clinical course and characteristic clinicopathologic features. In adult patients, however, greater clinicopathologic and cytogenetic heterogeneity, including occasional additional abnormalities such as BCL6 rearrangement, may be observed. Accurate identification of IRF4 rearrangement is critical for differential diagnosis and may also have implications for clinical management, particularly when interpreted in conjunction with patient age and clinicopathologic features.
Indexed as
Identifiers
42726346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.